TO THE EDITOR:

Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk subtype of B-precursor ALL (B-ALL) characterized by a gene-expression profile similar to Ph+ ALL but lacking the specific BCR-ABL1 fusion gene.1,2  Patients with Ph-like ALL are at higher risk of induction failure or high postinduction minimal residual disease (MRD) levels.3-5  This poor early response translates into inferior outcome in event-free survival (EFS) and overall survival (OS) as compared with other B-ALL patients. Ph-like ALL was recognized as a provisional entity by the 2016 World Health Organization (WHO) classification but strict and unequivocal diagnosis criteria have not yet been established. Ph-like ALL harbors diverse oncogenic lesions that all lead to the aberrant activation of cytokine receptors or signaling factors, the most frequent being rearrangements of CRLF2, fusions and mutations of JAK kinases, and fusions involving...

You do not currently have access to this content.